Neuroimmunological diseases are chronic diseases with an evolutionary burden of disabilities, often unpredictable and affect young adults influencing personal and professional life choices. Among these, we can include the neuromyelitis optic spectrum disorder (NMOSD), a rare disease with still a high therapeutic need to satisfy. Satraliizumab, a monoclonal antibody targeting the IL6 receptor, represents an important therapeutic innovation because it targets a critical proinflammatory cytokine, fundamental for the immunopathogenesis of NMOSD and also for other neuroimmunological pathologies including Myasthenia Gravis, Autoimmune Encephalitis and MOGAD.